Constantine (“Dino”) Koutsoubas works with generic pharmaceutical manufacturers in their efforts to bring their products to market.  In this role, he helps clients in every aspect of Hatch-Waxman Act litigation, from drafting the initial Paragraph IV notice letter to trial.

Dino is appreciated for his advocacy abilities, both in and out of court.  Dino’s even-tempered communication style and consistently solid judgment is enhanced by his dedication to achieving the right result for every client he serves.  Dino consistently delivers the acute skill of analyzing each case and identifying arguments that have the best chance of succeeding.  An avid team player, Dino strives to maximize his client’s time and resources at every turn.

Dino also brings to bear his knowledge in complex scientific issues to advise companies on emerging technologies, including cryptocurrency and non-fungible tokens.  His experience includes the minting of NFTs and advising on contractual rights associated with digital assets.

Prior to law school, Dino held a process engineering/research pharmacist role at a major pharmaceutical company, where he was responsible for scaling-up solid dosage form formulations from the clinical scale to the commercial scale validation batches.  In that role, he learned each unit operation involved in making tablets, capsules and soft gels.  For his products, he was ultimately responsible for preparing the process development reports for the New Drug Application.

Prior to joining Kelley Drye, Dino was an associate in the patent litigation group of a major Chicago-based firm, where he represented both plaintiffs and defendants at both the trial and appellate level.
 

Hatch-Waxman Matters

Otsuka Pharm. Co., Ltd. v. Lupin Limited et al., 14–7105 (JBS) (KMW) (D.N.J.) (aripiprazole tablets)

Endo Pharms. Solutions Inc. et al. v. Paddock Laboratories, LLC et al., No. 14–01422 (D. Del.) (SLR) (testosterone undecanoate injection)

Kowa Co. Ltd. et al. v. Lupin Limited et al., 15–3935 (PAC) (S.D.N.Y.) (pitavastatin calcium tablets)

AstraZeneca AB et al. v. Lupin Limited et al., 15–6092 (MLC) (TJB) (D.N.J.) (esomeprazole magnesium delayed-release capsules)

Forest Labs., LLC v. Lupin Limited et al., 14–1058 (D. Del.) (memantine HCl extended-release capsules)

Fresenius Kabi USA, LLC et al. v. Mylan Laboratories Limited et al., 15–942 (LPS) (D. Del.) (ropivacaine HCl injection)

Shire, LLC v. CorePharma, LLC, 14–05694 (RMB) (JS) (D.N.J.) (mixed amphetamine salts extended-release capsules)

UCB, Inc. v. CorePharma, LLC, 14–01788 (RMB) (KMW) (D.N.J.) (methylphenidate HCl extended-release capsules)

Spectrum Pharms., Inc. et al. v. InnoPharma, Inc. et al., 12–260 (RGA) (CJB) (D. Del.) (levoleucovorin injection)

AstraZeneca Pharms. LP et al. v. Lupin Limited et al., 12–6888 (JAP) (TJB) (D.N.J.) (quetiapine fumarate extended-release tablets)

Merck Sharp & Dohm Corp. et al. v. Mylan Pharms., Inc., 09–6383 & 10–3085 (JLL) (MAH) (D.N.J.) (ezetimibe & ezetimibe/simvastatin)

Schering Corp. v. Glenmark Pharms., Inc., USA, 07–1334 (JLL) (ES) (D.N.J.) (ezetimibe)

Orexo AB v. Mylan Pharms., Inc.I11–3788 (FLW) (LHG) (D.N.J.) (zolpidem tartrate sublingual tablets)

Other Patent Cases

Hudson Surgical Design, Inc. v. DePuy Orthopaedics, Inc., No. 10–463 (JD) (CAN) (N.D. Ind.) (knee implant technology)

ArcelorMittal v. AK Steel et al., No. 2011–1638 (Fed. Cir.) (cold-rolled steel)

Alma Lasers, Ltd. v. Thermage, Inc., No. 07–224 (GMS) (D. Del.) (cosmetic lasers)

BorgWarner, Inc. et al v. Hilite Int’l, Inc. et al., No. 07–3339 (N.D. Ill.) (variable camshaft timing)

Hochstein v. Microsoft Corp., No. 04–73071 (PDB) (DAS) (E.D. Mich.), No. 2010–1551 (Fed. Cir.) (video game console)

Hydronics, Inc. v. Pfizer, Inc., AAA Case No. 54 193 Y 00936 08 (animal vaccine)

Lineage Power Corp. v. SynQor, Inc., No. 08–0095 (TJW) (CE) (E.D. Tex.) (power converters)
 

Dino was selected as one of Illinois Super Lawyers "Rising Stars," 2015-2019.
 

Hellenic Bar Association, director and judicial evaluation committee member